We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Co-founder and Chief Scientific Officer.
Bought into the placing at 9p but apparently only fo appearances sake. Selling off as soon as the SP dropped back to the placing price is not a vote of confidence.
It's all a bit tragic. Good science going to waste because they are clueless about commercialisation.
When the co-founder takes his holding just below the declarable level of 3%.
As a brief follow up to my GP visit , I sent him an extract from the rns that explains the PSE test within the context of PSA testing an d also a link to the company's website. I feel that I have likely achieved more than the OBD marketing team and will keep banging the drum with friends and family . I only wish I could see more results from others!
Unless the board starts posting regulary and very positive trading updates, mainly on test sales, I really really cant see the share price staying at this level.
it will drop quite significantly on very few positive trading statements.
I think the markets can see Oxford are not treading water .
No doubt any negative problems that will be anounced by Oxford. None will be the boards fault !!
It will be anything but theirs.
Hi Taverham
I`ve been following Oxford on Linkedin and very few people few their posts,
The vast majority that do are generally emploees.
I feel that Burrows has made such a mess of this that very few people care about the company anymore.
I`m really not sure they can come back from this fiasco.
Not enough sales by september, and profits being made, another funding round will defo be needed by december and how I see it the shares will be much lower than this.
That means a far greater number of shares needed to fund Burrows and the boards wages for another 12 months.
Will the company crash or go private, either way its not look good for shareholders.
The stratergy the board has implemented and Burrows arrogance has cost us all dearly.
Kong
Kong, thanks for the linkedin info - not many people have viewed it ,in fact it is clear that not every employee of the company has viewed it let alone reposted it!
Not sure if anyone is on LinkedIn, but Oxford have posted that they are now live in the UK and have done some tests already.
To my amazement they say Theve been sending samples to America for testing .
The expense and logistics is totally stupid
Hi
A specialist MRI can support staging a prostate cancer but not to detect early possible cancer . However the 750 pound cost of the test prevents it from becoming a screening tool .
It may be used once a prostate cancer is suspected either from a raised PSA result or possible from feeling an hard irregular prostate with symptoms .
If the price was dropped and they had far better data on populations then it could be come a tool for national screening .
Actually, just spotted one trade slightly lower @8.8375 was a sell
@8.88 being the lowest price of the day, must be a sell!
£44k so one knows
Might be worth dropping a line to the BUPA marketing g woman that was welcoming the deal via LinkedIn and ask her how many CiRTs they have bought to date and if the agreement to buy was unconditional which is the tone of the OBD RNS. It now feels like it was likely subject to recommendation by BUPA consultants hence the semi ar series to be ran this year. If I'm rightin that suspicion then the RNS was clearly misleading.
Dug, thanks - but to prove it is misleading we would need Bupa [ideally] or a number of patients to say that never happened , and even if we proved that , the statement is one of intent and his lawyer would say an honest intent.
Any other ideas?
Meanwhile anyone got any idea as to why someone would elect for a PSE at £750 in place of a MRI at £300?
In another indication that liquid biopsy technology is a rapidly growing and competitive segment a new Alzheimers test is to leverage funding from charity and NIHR to secure rapid validation at scale.
Sounds kinda like Transform Prostate which Burrows said OBD 'must be involved in'. Shame he seems to have forgotten to include this 'must do' in his recent description of key corporate goals for the coming year. .
Hi Tav,
I think the following from the BUPA RNS could well be deemed to be misleading given that the latest information suggests the ongoing interaction with BUPA is to be a series of seminars for medics.
"Bupa UK health insurance customers being considered for checkpoint inhibitor immunotherapy will now be offered the smart blood test, which accurately predicts a cancer patient's response to the treatment
· The OBD Bupa UK partnership significantly enhances access to CiRT in the UK and reflects Bupa's commitment to leveraging advanced precision medicine testing to transform cancer care"
So the question is what %age of BUPA patients being considered for checkpoint immunotherapy have been offered the CiRT test to date?I strongly suspect the answer as of today would be zero. We certainly know that total sales of CiRT continued at a ludicrously low level at the last update, and most of those will be attributable to the US.
Kong, what specifically can you point to; i.e rns number x quotes etc? If you can do that I am happy to write to FCA - have done so before.
Meanwhile I asked my gp what he knew about PSE tests and it was clear he had never heard of them. I explained what i knew and he said ' why would you bother with a PSE test for £750 if a MRI is £300 ? ' I said I thought it was all about accuracy and avoidance of unnecessary biopsys and i would happily pay for ither or both it reduced my worries. He also said there would need to be transport to the Oxford lab [ 40 miles] and ideally the tests would need to be rolled out to the other labs where the logistics were sorted. I was thinking of sending him a folllow up email and should be grateful for anything I can say that answers the question , why a PSE in place of a MRI. Comments gratefully recieved.
There was two buys of £41,000 . It said unknown last night.. 500, 000 shares.
..£18.14k
Dugwalker
Burrows should be legally charged with false misleading information.
Investors have lost huge amounts on his lies
He, the board and the Nomads should be accountable for allowing false news information
The FSA should start taking responsibility otherwise AIM is going to cease.
AIM is a disgrace at the moment
Kong
I am seeing my gp about another matter but , assuming time allows , ask what they think of PSE tests. Just now I am thinking that they will have heard nothing - we shall see and I will report back.
It appears to be a characteristic of this mob that they push out a 'positive' RNS to bump.up the share price whilst deliberately holding back an altogether less positive RNS just a few hours later.
Whatever happened to the non-dilutive financing all those named 3rd parties were clamouring to provide according to the greediest piggy?
We really can't believe a word they say.
404x
It’s a disgrace
The nomads should be accountable just as much for allowing misleading information out.
Is the rot to deep for the company to come back from.
Burrows was paid £588k in 2023 (the latest period they've given details for), plus retirement benefits, plus hundreds of thousands of warrants. Annual report has details, including his daughter's remuneration.
His total salary last year was already an increase of more than 15% from £506k the previous year, so for this year assume it's increased from the £588k further still.
One great deal .. yes it will fly - if you can believe whatever the "deal announced" is true. Am sat on a nasty loss probably like others but will just stick with it and cross something or other.
I cant see how ceo gets 400k a year on this turnover no wonder a 10 million loss .LOVE the product but not the expenses . However one great deal this could hit 50p